Moderna ( ($MRNA) ) has released its Q4 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...
TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company ...
Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.
Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech ...
An interdisciplinary research team from Leipzig University and the Saxon AI center ScaDS.AI has developed a novel approach ...
As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...
Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...
Viral diseases remain a significant global health challenge, causing widespread morbidity and mortality. Advances in ...
Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...
Operator: Thank you for standing by, and welcome to the Origin Agritech Fiscal Year 2024 Conference Call. Please note that, today ...